Literature DB >> 3987800

Pharmacokinetic study of i.v. infusions of adriamycin.

S Eksborg, H S Strandler, F Edsmyr, I Näslund, P Tahvanainen.   

Abstract

The plasma pharmacokinetics of adriamycin has been studied in 21 cancer patients (31-85 years old) without liver tumours after short (3.00 min) and prolonged (45 min-16 h) i.v. infusions. The area under the plasma concentration-time curve and the maximum plasma concentration compensated for dose variation showed a more than 3-fold individual variation. The pharmacokinetics of adriamycin was linear. There was no pharmacokinetic rational for variation of the dose with the age of the patients. There was good agreement between the measured plasma concentration-time curves for prolonged infusions and curves predicted from pharmacokinetic data from short term infusions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987800     DOI: 10.1007/bf00609693

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  34 in total

1.  Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report.

Authors:  M M Bern; W McDermott; B Cady; R A Oberfield; C Trey; M E Clouse; J L Tullis; L M Parker
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

2.  Pharmacokinetics and metabolism of adriamycin in man.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  Evidence of possible dose-dependent doxorubicin plasma kinetics in man.

Authors:  R C Boston; D R Phillips
Journal:  Cancer Treat Rep       Date:  1983-01

4.  Age dependence of the early-phase pharmacokinetics of doxorubicin.

Authors:  J Robert; B Hoerni
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

5.  Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis.

Authors:  K K Chan; R T Chlebowski; M Tong; H S Chen; J F Gross; J R Bateman
Journal:  Cancer Res       Date:  1980-04       Impact factor: 12.701

6.  Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.

Authors:  S Eksborg; B J Cedermark; H S Strandler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

7.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

8.  [Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas].

Authors:  J Robert; P Vrignaud; A Iliadis; H Eghbali; B Hoerni
Journal:  Nouv Rev Fr Hematol       Date:  1983

9.  Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer.

Authors:  S S Legha; R S Benjamin; B Mackay; H Y Yap; S Wallace; M Ewer; G R Blumenschein; E J Freireich
Journal:  Cancer       Date:  1982-05-01       Impact factor: 6.860

10.  Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects.

Authors:  R T Chlebowski; K K Chan; M J Tong; J M Weiner; V M Ryden; J R Bateman
Journal:  Cancer       Date:  1981-09-01       Impact factor: 6.860

View more
  16 in total

1.  Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.

Authors:  J M Jacquet; F Bressolle; M Galtier; M Bourrier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Pharmacokinetics of 4' epi-adriamycin after morning and afternoon intravenous administration.

Authors:  S Eksborg; U Stendahl; K Antila
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration.

Authors:  S Eksborg; U Stendahl; U Lönroth
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  A pharmacokinetic study of adriamycin and 4'epi-adriamycin after simultaneous intra-arterial liver administration.

Authors:  S Eksborg; M Andersson; L Domellöf; U Lönroth
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

5.  Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.

Authors:  Swantje Völler; Joachim Boos; Miriam Krischke; Gudrun Würthwein; Nina E Kontny; Alan V Boddy; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

7.  A tumor cord model for doxorubicin delivery and dose optimization in solid tumors.

Authors:  Steffen Eikenberry
Journal:  Theor Biol Med Model       Date:  2009-08-09       Impact factor: 2.432

8.  Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.

Authors:  B J Cusack; S P Young; J Driskell; R D Olson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study.

Authors:  S Eksborg; L Hardell; N O Bengtsson; M Sjödin; B Elfsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

10.  Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.

Authors:  C J Twelves; N A Dobbs; M Aldhous; P G Harper; R D Rubens; M A Richards
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.